Oxcarbazepine
| Evidence Level: L3 | Predicted Indications: 10 |
Table of Contents
Oxcarbazepine: From Epilepsy to Visual Epilepsy
One-Sentence Summary
Oxcarbazepine is an established antiepileptic drug (the keto-analogue of carbamazepine) used for partial-onset and generalised tonic-clonic seizures. The TxGNN model predicts it may also be effective for Visual Epilepsy, a photosensitive/reflex epilepsy subtype, with 1 clinical trial and 20 publications currently identified as related evidence — though none of these studies specifically investigates visual/photosensitive epilepsy as a distinct entity.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Epilepsy (partial-onset seizures) — inferred from the supporting literature in this evidence pack; no formal indication text was supplied |
| Predicted New Indication | Visual Epilepsy |
| TxGNN Prediction Score | 99.95% |
| Evidence Level | L3 |
| UK Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this evidence pack. Based on the supporting literature, Oxcarbazepine is a sodium-channel-blocking anticonvulsant, structurally derived from carbamazepine, which limits high-frequency neuronal firing and stabilises hyperexcitable membranes — a mechanism directly relevant to seizure suppression regardless of trigger type.
Visual epilepsy (photosensitive/reflex epilepsy) is not a separate disease from epilepsy in the pharmacological sense — it is a seizure-triggering phenotype that sits within the same broad epilepsy spectrum that oxcarbazepine is already used to treat. This is therefore less a “new indication” in the traditional repurposing sense and more a plausible extension of an existing, well-established use into a specific epilepsy subtype.
However, it is important to note that none of the identified trials or literature specifically studies visual/photosensitive epilepsy; the evidence base consists of general antiepileptic drug (AED) literature and broad-spectrum efficacy trials. The mechanistic rationale is sound, but disease-specific clinical confirmation is currently absent.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrolment | Key Findings |
|---|---|---|---|---|
| NCT00855738 | Phase 4 | Completed | 111 | LICEO study: prospective observational assessment of new AEDs (including oxcarbazepine) as first-choice bitherapy in daily clinical practice for focal epilepsy; not specific to visual/photosensitive seizures |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 35429132 | 2022 | RCT | CNS Neurosci Ther | Multicentre, open-label, randomised study comparing oxcarbazepine vs levetiracetam monotherapy in newly diagnosed focal epilepsy in China |
| 27845825 | 2016 | Systematic Review (Cochrane, withdrawn) | Cochrane Database Syst Rev | Oxcarbazepine add-on for drug-resistant partial epilepsy |
| 35380580 | 2022 | Review | JAMA | Overview of antiseizure medications for adults with epilepsy |
| 39899099 | 2025 | Review | Continuum (Minneap Minn) | Updated review of antiseizure medication therapy, including oxcarbazepine |
| 33334546 | 2020 | Review | Seizure | Current role of carbamazepine and oxcarbazepine in epilepsy management amid newer AEDs |
| 26844734 | 2016 | Review | Continuum (Minneap Minn) | Individual antiepileptic drug profiles including pharmacokinetics and indications |
| 37092337 | 2023 | Review | Pharmacogenomics | Pharmacogenomic variability affecting oxcarbazepine efficacy and safety |
| 12697143 | 2003 | Observational | Epilepsy Behav | Safety and tolerability of oxcarbazepine in elderly vs adult epilepsy patients |
| 22091603 | 2012 | Clinical Study | Epilepsia | Efficacy, tolerability and pharmacokinetics of oxcarbazepine oral loading in epilepsy |
| 11772334 | 2002 | Review | Expert Opin Pharmacother | Oxcarbazepine efficacy in partial-onset seizures, trigeminal neuralgia and neuropathic pain |
UK Market Information
No UK marketing authorisations for Oxcarbazepine are recorded in this evidence pack (market status: Not marketed; total authorisations: 0). This should be independently verified against the current MHRA product database, as branded and generic oxcarbazepine products (e.g. Trileptal) have historically held UK marketing authorisations for epilepsy.
Safety Considerations
A Blocking data gap has been identified for this candidate: no MHRA/SmPC-equivalent warnings, contraindications or drug interaction data were available for review, meaning safety cannot currently be assessed. Please refer to the SmPC and BNF for authoritative safety information once located, and report suspected adverse reactions via the Yellow Card Scheme.
Conclusion and Next Steps
Decision: Hold
Rationale: A blocking data gap exists — no SmPC-equivalent warnings, contraindications or interaction data are available, which prevents even an initial safety screen. In addition, no disease-specific clinical evidence for visual/photosensitive epilepsy was found (all evidence is general AED/epilepsy literature), and the drug currently has no UK marketing authorisation on record.
To proceed, the following is needed:
- MHRA-equivalent SmPC data (warnings, contraindications, drug interactions) to clear the blocking data gap
- Confirmation of current UK marketing authorisation status (this evidence pack shows none, which should be verified)
- Detailed mechanism of action (MOA) documentation
- Disease-specific evidence (case series, observational studies, or trials) addressing visual/photosensitive epilepsy specifically, rather than general focal epilepsy
- Route and formulation compatibility assessment for the target population
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.